EUVIMEDEUVIMED entdecken
Crossref

A Multifunctional Porous Silicon Nanocarrier for Glioblastoma Treatment

Meihua Luo iD, Yuchen Li, Bo Peng, Jacinta White, Ermei Mäkilä, Wing Yin Tong, Chung Hang Jonathan Choi iD, Bryan Day, Nicolas H Voelcker iD

Molecular Pharmaceutics · 02.01.2023 · 20 (1) · 545-560

DOI: 10.1021/acs.molpharmaceut.2c00763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 09.12.2022. Verfasst von Meihua Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria3052, Australia. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Research Grants Council, University Grants Committee, Monash University, Croucher Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical treatment of glioblastoma (GBM) remains a major challenge because of the blood-brain barrier, chemotherapeutic resistance, and aggressive tumor metastasis. The development of advanced nanoplatforms that can efficiently deliver drugs and gene therapies across the BBB to the brain tumors is urgently needed. The protein "downregulated in renal cell carcinoma" (DRR) is one of the key drivers of GBM invasion. Here, we engineered porous silicon nanoparticles (pSiNPs) with antisense oligonucleotide (AON) for DRR gene knockdown as a targeted gene and drug delivery platform for GBM treatment. These AON-modified pSiNPs (AON@pSiNPs) were selectively internalized by GBM and human cerebral microvascular endothelial cells (hCMEC/D3) cells expressing Class A scavenger receptors (SR-A). AON was released from AON@pSiNPs, knocked down DRR and inhibited GBM cell migration. Additionally, a penetration study in a microfluidic-based BBB model and a biodistribution study in a glioma mice model showed that AON@pSiNPs could specifically cross the BBB and enter the brain. We further demonstrated that AON@pSiNPs could carry a large payload of the chemotherapy drug temozolomide (TMZ, 1.3 mg of TMZ per mg of NPs) and induce a significant cytotoxicity in GBM cells. On the basis of these results, the nanocarrier and its multifunctional strategy provide a strong potential for clinical treatment of GBM and research for targeted drug and gene delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsAnimalsMiceHumansSiliconPorosityEndothelial CellsTissue DistributionCell Line, TumorTemozolomideDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Antisense oligonucleotidesblood−brain barrierdrug deliverygene deliveryglioblastomaporous silicon nanoparticles

Substanzen

SiliconTemozolomide

Autor:innen und Institutionen

  • Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria3052, Australia.
  • Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, St. Lucia, Queensland4072, Australia.
  • Cell and Molecular Biology Department, QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Brisbane, Queensland4006, Australia.
  • Frontiers Science Center for Flexible Electronics, Xi'an Institute of Flexible Electronics (IFE) and Xi'an Institute of Biomedical materials & Engineering, Northwestern Polytechnical University, Xi'an710072, China.
  • Commonwealth Scientific and Industrial Research Organization (CSIRO), Clayton, Victoria3168, Australia.
  • Industrial Physics Laboratory, Department of Physics and Astronomy, University of Turku, Turku20014, Finland.

ORCID-Profile: Meihua Luo, Chung Hang Jonathan Choi, Nicolas H Voelcker

Förderung

  • Research Grants Council, University Grants Committee
  • Monash University
  • Croucher Foundation
  • Chinese University of Hong Kong
  • Chow Yuk Ho Technology Centre for Innovative Medicine, Chinese University of Hong Kong

Zitieren

APA

Luo, M., Li, Y., Peng, B., White, J., Mäkilä, E., Tong, W. Y., Jonathan Choi, C. H., Day, B., & Voelcker, N. H. (2023). A Multifunctional Porous Silicon Nanocarrier for Glioblastoma Treatment. Molecular Pharmaceutics, 20(1), 545-560. https://doi.org/10.1021/acs.molpharmaceut.2c00763

Vancouver

Luo M, Li Y, Peng B, White J, Mäkilä E, Tong WY, et al. A Multifunctional Porous Silicon Nanocarrier for Glioblastoma Treatment. Molecular Pharmaceutics. 2023;20(1):545-560. doi:10.1021/acs.molpharmaceut.2c00763

BibTeX
@article{Luo2023,
  author = {Luo, Meihua and Li, Yuchen and Peng, Bo and White, Jacinta and Mäkilä, Ermei and Tong, Wing Yin and Jonathan Choi, Chung Hang and Day, Bryan and Voelcker, Nicolas H},
  title = {A Multifunctional Porous Silicon Nanocarrier for Glioblastoma Treatment},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {1},
  pages = {545--560},
  doi = {10.1021/acs.molpharmaceut.2c00763}
}
Kostenlos starten →